ユルトミリス（ULTOMIRIS）の新興薬剤に関する洞察と市場予測：2032年

ユルトミリス（ラブリズマブ）は、最初で唯一の長時間作用型C5補体阻害薬であり、即効性、完全性、持続性の補体阻害作用を有します。この薬剤は、身体の免疫システムの一部である終末補体カスケードのC5タンパク質を阻害することで作用します。補体カスケードは、制御されずに活性化すると過剰に反応し、健康な細胞を攻撃します。ユルトミリスは、成人患者に8週間ごとに静脈内投与されます。

今後数年間で、皮膚筋炎の市場シナリオは、世界中の広範な調査と増加するヘルスケア支出のために変化します。各社は、病状を治療／改善するための新たなアプローチに焦点を当てた治療法を開発し、課題を評価し、ユルトミリスの優位性に影響を与える可能性のある機会を模索しています。他の皮膚筋炎治療薬もユルトミリスと厳しい市場競争を繰り広げることが予想され、近い将来、後発の新興治療薬が上市されれば、市場に大きな影響を与えると予測されています。

当レポートでは、主要7ヶ国におけるユルトミリス市場について調査し、市場の概要とともに、2024年～2032年の売上予測データ、競合情勢、および国別動向などを提供しています。

目次

第1章 レポートのイントロダクション

第2章 皮膚筋炎に対するユルトミリスの概要

• 製品の詳細
• 臨床開発
  • 臨床研究
  • 臨床試験情報
  • 安全性と有効性
• その他の開発活動
• 製品概要

第3章 競合情勢（後期段階の新興治療法）

第4章 ユルトミリスの市場評価

• 皮膚筋炎に対するユルトミリスの市場展望
• 主要7ヶ国市場分析
  • 主要7ヶ国における皮膚筋炎に対するユルトミリスの市場規模
• 国別市場分析
  • 米国
  • ドイツ
  • 英国

第5章 SWOT分析

第6章 アナリストの見解

第7章 付録

第8章 DelveInsightのサービス内容

第9章 免責事項

第10章 DelveInsightについて

第11章 レポート購入オプション

List of Tables

• Table 1: ULTOMIRIS, Clinical Trial Description, 2023
• Table 2: ULTOMIRIS, General Description
• Table 3: Competitive Landscape (Emerging Therapies)
• Table 4: ULTOMIRIS Market Size in the 7MM, in USD million (2019-2032)
• Table 5: ULTOMIRIS Market Size in the US, in USD million (2019-2032)
• Table 6: ULTOMIRIS Market Size in Germany, in USD million (2019-2032)
• Table 7: ULTOMIRIS Market Size in France, in USD million (2019-2032)
• Table 8: ULTOMIRIS Market Size in Italy, in USD million (2019-2032)
• Table 9: ULTOMIRIS Market Size in Spain, in USD million (2019-2032)
• Table 10: ULTOMIRIS Market Size in the UK, in USD million (2019-2032)
• Table 11: ULTOMIRIS Market Size in Japan, in USD million (2019-2032)

List of Figures

• Figure 1: ULTOMIRIS Market Size in the 7MM, USD million (2019-2032)
• Figure 2: ULTOMIRIS Market Size in the United States, USD million (2019-2032)
• Figure 3: ULTOMIRIS Market Size in Germany, USD million (2019-2032)
• Figure 4: ULTOMIRIS Market Size in France, USD million (2019-2032)
• Figure 5: ULTOMIRIS Market Size in Italy, USD million (2019-2032)
• Figure 6: ULTOMIRIS Market Size in Spain, USD million (2019-2032)
• Figure 7: ULTOMIRIS Market Size in the United Kingdom, USD million (2019-2032)
• Figure 8: ULTOMIRIS Market Size in Japan, USD million (2019-2032)

“"ULTOMIRIS Emerging Drug Insight and Market Forecast - 2032" ” report provides comprehensive insights about ULTOMIRIS for dermatomyositis in the seven major markets. A detailed picture of the ULTOMIRIS for dermatomyositis in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the ULTOMIRIS for dermatomyositis. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the ULTOMIRIS market forecast analysis for dermatomyositis in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in dermatomyositis.

Drug Summary:

ULTOMIRIS (ravulizumab), the first and only long-acting C5 complement inhibitor, offers immediate, complete, and sustained complement inhibition. The medication works by inhibiting the C5 protein in the terminal complement cascade, a part of the body's immune system. When activated uncontrolled, the complement cascade over-responds, leading the body to attack its healthy cells. ULTOMIRIS is administered intravenously every 8 weeks in adult patients, following a loading dose.

The company is actively recruiting for its registration Phase II/III study, which started in December 2021 and is expected to be completed by November 2024.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the ULTOMIRIS description, mechanism of action, dosage and administration, research and development activities in dermatomyositis.
• Elaborated details on ULTOMIRIS regulatory milestones and other development activities have been provided in this report.
• The report also highlights the ULTOMIRIS research and development activities in dermatomyositis across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around ULTOMIRIS.
• The report contains forecasted sales of ULTOMIRIS for dermatomyositis till 2032.
• Comprehensive coverage of the late-stage emerging therapies for dermatomyositis.
• The report also features the SWOT analysis with analyst views for ULTOMIRIS in dermatomyositis.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

ULTOMIRIS Analytical Perspective by DelveInsight

In-depth ULTOMIRIS Market Assessment

This report provides a detailed market assessment of ULTOMIRIS for dermatomyositis in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.

ULTOMIRIS Clinical Assessment

The report provides the clinical trials information of ULTOMIRIS for dermatomyositis covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for dermatomyositis is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence ULTOMIRIS dominance.
• Other emerging products for dermatomyositis are expected to give tough market competition to ULTOMIRIS and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of ULTOMIRIS in dermatomyositis.
• Our in-depth analysis of the forecasted sales data of ULTOMIRIS from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the ULTOMIRIS in dermatomyositis.

Key Questions:

• What is the product type, route of administration and mechanism of action of ULTOMIRIS?
• What is the clinical trial status of the study related to ULTOMIRIS in dermatomyositis and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the ULTOMIRIS development?
• What are the key designations that have been granted to ULTOMIRIS for dermatomyositis?
• What is the forecasted market scenario of ULTOMIRIS for dermatomyositis?
• What are the forecasted sales of ULTOMIRIS in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to ULTOMIRIS for dermatomyositis?
• Which are the late-stage emerging therapies under development for the treatment of dermatomyositis?

Table of Contents

1. Report Introduction

2. ULTOMIRIS Overview in Dermatomyositis

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Late-stage Emerging Therapies)

4. ULTOMIRIS Market Assessment

• 4.1. Market Outlook of ULTOMIRIS in dermatomyositis
• 4.2. 7MM Analysis
  • 4.2.1. Market Size of ULTOMIRIS in the 7MM for dermatomyositis
• 4.3. Country-wise Market Analysis
  • 4.3.1. Market Size of ULTOMIRIS in the United States for dermatomyositis
  • 4.3.2. Market Size of ULTOMIRIS in Germany for dermatomyositis
  • 4.3.3. Market Size of ULTOMIRIS in France for dermatomyositis
  • 4.3.4. Market Size of ULTOMIRIS in Italy for dermatomyositis
  • 4.3.5. Market Size of ULTOMIRIS in Spain for dermatomyositis
  • 4.3.6. Market Size of ULTOMIRIS in the United Kingdom for dermatomyositis
  • 4.3.7. Market Size of ULTOMIRIS in Japan for dermatomyositis

5. SWOT Analysis

6. Analysts' Views

7. Appendix

• 7.1. Bibliography
• 7.2. Report Methodology

8. DelveInsight Capabilities

9. Disclaimer

10. About DelveInsight

11. Report Purchase Options